Skip to main content
. Author manuscript; available in PMC: 2013 Mar 3.
Published in final edited form as: Inflamm Bowel Dis. 2012 Jan 12;18(9):1698–1710. doi: 10.1002/ibd.22874

Figure 6.

Figure 6

CMP-treatment significantly suppresses chronic colitis development in TCRαKO mice by upregulating IFNγ production. (A) Histology score of PBS-fed (n=13) and chitin-fed (n=14) TCRα KO colitis mice was evaluated according to previous criteria. (B) BrdU was injected intraperitoneally 1 hour prior to the sacrifice of mice (n=6) and staining were done on the colonic tissue sections followed by positive cell numbers count per crypt. (C)Tissue homogenate cytokine levels in cecum, colon, spleen and mesenteric lymph nodes (MLN) were examined by ELISA (n=6). *P <.05; **P <.01.